Long-Term Outcomes of ABO-Incompatible Versus Compatible Living Donor Liver Transplantation: A Single-Center Retrospective Study
Conditions: Liver Transplantation, Liver Diseases
Sponsor: Seoung Hoon Kim

ClinicalTrials.gov Registration Summary 
July 1, 2025 
Study Title 
Long-Term Outcomes of ABO-Incompatible Versus Compatible Living Donor Liver 
Transplantation: A Single-Center Retrospective Study 
Brief Summary 
This retrospective cohort study investigates the long-term outcomes of ABO-incompatible 
(ABO-I) versus ABO-compatible (ABO-C) living donor liver transplantation (LDLT). A total 
of 511 patients underwent LDLT between January 2012 and December 2022 at a single 
high-volume transplant center in Korea. Among them, 121 received ABO-I grafts using a 
rituximab-based desensitization protocol, while 390 underwent ABO-C LDLT. The study 
aims to compare overall survival and the incidence of biliary complications, as well as to 
identify risk factors specific to each group. This analysis provides insights into the long-
term safety and efficacy of ABO-I LDLT in regions with low deceased donor organ 
availability. 
Study Type 
Observational 
Retrospective Cohort 
Enrollment 
511 (Actual) 
Study Dates 
Study Start Date: January 1, 2012 
Study Completion Date: December 31, 2022 
Primary Completion Date: December 31, 2022 
Primary Outcome Measure 
Incidence of biliary complications (Time Frame: within 10 years post-transplantation) 

Secondary Outcome Measures 
• Overall patient survival (Time Frame: 3-, 5-, 10-year) 
• Incidence of acute cellular rejection (Time Frame: 1 year) 
• Hospital stay duration (Time Frame: up to 30 days post-transplant) 
Biospecimen Retention 
None 
Conditions 
• Liver Disease 
• Liver Transplantation 
Intervention 
None (Observational study) 
Eligibility Criteria 
Inclusion: All adult patients who underwent LDLT at the study center from 2012 to 2022. 
Exclusion: Pediatric patients, deceased donor recipients, multi-organ transplants. 
Study Location 
Center Name: National Cancer Center 
City: Goyang 
Country: South Korea 
Responsible Party 
Principal Investigator: Dr. Seoung Hoon Kim 
Institution: National Cancer Center 
Contact Email: kshlj@hanmail.net 
Ethics Approval 
Approved by Institutional Review Board of National Cancer Center 
Approval Number: NCC2023-0110